Výsledky léčby nemocných s esenciální trombocytémií a dalšími myeloproliferacemi provázenými trombocytémií-zpráva z registru pacientů léčených Thromboreductinem

• Title in English: The results of the treatment of patients with essential thrombocythemia and other myeloproliferation-related thrombocythemia-a report of patients treated with Thromboreductin
• Authors: PENKA Miroslav; SCHWARZ Jiří; PAVLÍK Tomáš; INDRÁK Karel; DOUBEK Michael; DULÍČEK P.; POSPÍŠILOVÁ D.; KISSOVÁ Jarmila; JONÁŠOVÁ A.; JELÍNKOVÁ Pavla; HLUŠÍ A.; SCHUTZOVÁ M.; ČERNÁ O.; BRYCHTOVÁ Yvona; NOVÁKOVÁ L.; KOŘÍSTEK Zdeněk; SEGETHOVÁ J.; VOZOBULOVÁ Jaroslava; HADAČOVÁ I.; HOCHOVÁ I.; VOGLOVÁ J.; WALTEROVÁ L.; BODZÁSOVÁ C.; DUŠEK Ladislav
• Year of publication: 2009
• Type: Article in Periodical
• Magazine / Source: Vnitřní Lékařství
• MU Faculty or unit: Faculty of Medicine
• Field: Oncology and hematology
• Keywords: essential thrombocythemia; myeloproliferation; Thromboreductin; patient registry
• Description: The registry of patients treated with Thromboreductin (anagrelide) in the Czech Republic contains data concerning patients that have been treated using this drug since 2004. As of June 2009, the total number of patients was 549. The current analysis focused mainly on evaluation of anagrelide dosage needed to achieve a complete response in high-risk patients: reduction in platelet count to below 400 x 10(9)/l, which was also considered as reaching the therapeutic goal. The outcomes of the registry confirm that although anagrelide (Thromboreductin) is a very effective platelet-reducing agent, the administration of which is related to a low incidence of adverse effects and complications, the therapeutic goal is not achieved in all cases and or despite a quick treatment response, the therapeutic goal is achieved more slowly.